Ozarelix is a potent gonadotropin-releasing hormone (GnRH) antagonist used in the biomedical industry for the treatment of prostate cancer. It efficiently inhibits the release of luteinizing hormone and follicle-stimulating hormone, thereby reducing androgen production and suppressing tumor growth. With its targeted action, Ozarelix offers a promising therapeutic solution for patients battling this malignancy.
CAT No: R2000
CAS No: 295350-45-7
Synonyms/Alias: Ozarelix;295350-45-7;Ozarelix [INN];UNII-Q1IF8M2YL3;Q1IF8M2YL3;D 63153;DTXSID60183722;D-63153;D-63 153;Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-NMe-Tyr-D-Hcit-Nle-Arg-Pro-D-Ala-NH2;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-norleucyl-L-arginyl-L-prolyl-;AC-D-2-NAL-D-4-CPA-D-3-PAL-SER-N-ME-TYR-D-HCI-NLE-ARG-PRO-D-ALA-NH2;AC-D-NAL(2)-D-PCL-D-PAL-SER-N-ME-TYR-D-HOMOCIT-NLE-ARG-PRO-D-ALA-NH2;N-ACETYL-3-(2-NAPHTHALENYL)-D-ALANYL-4-CHLORO-D-PHENYLALANYL-3-(3-PYRIDINYL)-D-ALANYL-L-SERYL-N-METHYL-L-TYROSYL-N6-(AMINOCARBONYL)-D-LYSYL-L-NORLEUCYL-L-ARGINYL-L-PROLYL-D-ALANINAMIDE;ozarelixum;Ozarelix acetate salt;H-Pro-Gly-NH2 . HCl;LHRH antagonist SPI-153;SCHEMBL19712249;DTXCID00106213;SPI-153;DB12581;DA-64267;FO110080;HY-16375;CS-0006308;D63153;D63 153;Q27286888;
Chemical Name: (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C72H96ClN17O14 |
M.W/Mr. | 1459.1 |
Sequence | One Letter Code:XXXSYXXRPA Three Letter Code:Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-N(Me)Tyr-D-hCit-Nle-Arg-Pro-D-Ala-NH2 |
InChI | InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1 |
InChI Key | KATZUZNTRINHDT-HALMFYTRSA-N |
Canonical SMILES | CCCCC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C |
Isomeric SMILES | CCCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C |
1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
5. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.